REGN is Regeneron Pharmaceuticals, Inc. (Healthcare). Trading at $638.88. Current dividend yield: 0.59%.
Dividend snapshot
| Annual dividend rate | $3.76 |
| Current yield | 0.59% |
| Payment frequency | Quarterly |
| Next ex-dividend date | May 20, 2026 |
| Most recent payment date | Jun 04, 2026 |
| Last payment amount | $0.9400 |
| 5-year dividend CAGR | — |
| 3-year dividend CAGR | — |
| Payout ratio | 9% |
| Market cap | $66.98B |
| Exchange | NMS |
Recent dividend payments
| Date | Amount / share |
|---|---|
| 2026-05-20 | $0.9400 |
| 2026-02-20 | $0.9400 |
| 2025-11-20 | $0.8800 |
| 2025-08-18 | $0.8800 |
| 2025-05-20 | $0.8800 |
| 2025-02-20 | $0.8800 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Track REGN in DiviDrip
Add REGN to your portfolio on DiviDrip to track every buy, DRIP reinvestment, and dividend payment in one place. Free, no credit card, no upsell — built by dividend investors, for dividend investors.
- Open DiviDrip — search REGN and add your shares.
- View the REGN Dividend Triangle — see Revenue × EPS × Dividend growth at a glance.
- Stock Screener — find more dividend payers like REGN.
- DiviDrip Learn — free guides on DRIP, dividend tiers, ETF comparisons.
Data refreshed 2026-05-23. Not investment advice. Yields and prices change continuously; always verify the latest numbers in the live app before buying.